NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
31/12/2024
Voltar para busca
Dado oficial do USPTO
EPIC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
EPIC
ST13
US500000097642362Classe
1, 5, 40, 42, 44
Pedido
97642362
Registro
7629331
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
46
Atualização mais recente
31/12/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 40, 42, 44
Data de depósito
21/10/2022
Data de registro
31/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/12/2024
Última transação
31/12/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Wien, AT
Examinador
CLYBURN, CARLA DIONNE
Unidade examinadora
M10
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
invIOs GmbH
Representantes
Michael J. Leonard FOX ROTHSCHILD LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 40Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Human immune cellsin particular T cellsfor scientific and medical research
Classe 5
Chemicalbiological and biochemical preparations and reagents for the cultivation of human immune cellsin particular T cellsfor medical purposes in the treatment of immuno-oncological diseases; Human immune cellsin particular T cellsfor medical or clinical purposes; biological preparations and pharmaceutical compositions containing human immune cellsin particular T cells for the treatment of immuno-oncological diseases; biological preparations and pharmaceutical preparations for use in medical and clinical cell therapyin particular immune cell therapyin particular T cell therapy; biological preparations and pharmaceutical composition containing human immune cellsin particular T-cellsfor the treatment of inflammatory diseasesdiseases of the immune system and cancer; biological preparations and pharmaceutical preparations containing human immune cellsin particular T-cellsfor the treatment of inflammatory diseasesdiseases of the immune system and cancer; biological preparations and pharmaceutical preparations in the form of living cells for use in the treatment of immuno-oncological diseases
Classe 40
Contract manufacturing of therapeutic medicinal productsContract manufacturing of cell therapies for the treatment of inflammatory diseasesdiseases of the immune system and cancer; Contract manufacturing for othersin particular manufacturing of pharmaceutical preparations for health carefor the treatment of people suffering from diseases treated by cell therapy or regenerative medicine productsmedicinal products for human use including investigational medicinal productsinvestigational biological productscell therapy preparations and advanced therapy medicinal productsall of the foregoing not in connection with medical diagnosticscancer diagnostics and cancer profiling
Classe 42
Development of biological and pharmaceutical medicinal products for the treatment of diseases using a cell therapy platform; all of the foregoing not in connection with medical diagnosticscancer diagnostics and cancer profiling
Classe 44
Medical services related to the treatment and preparation of human cells; medical servicesimmune cell therapy; medical servicesimmune cell modification; medical servicesadministration of immune cells; medical consulting related to immune cell therapyall of the foregoing not in connection with medical diagnosticscancer diagnostics and cancer profiling
Publicações
Histórico de despachos e eventos da marca no USPTO.
46 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
31/12/2024
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
09/12/2024
RG1B
REINSTATEMENT GRANTED - REQUEST TO DELETE 1(B) FILED
09/12/2024
MAB6
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
09/12/2024
ABN6
ABANDONMENT - NO USE STATEMENT FILED
09/12/2024
IUCN
NOTICE OF ALLOWANCE CANCELLED
07/05/2024
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
07/05/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/05/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/03/2024
PUBO
PUBLISHED FOR OPPOSITION
12/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/02/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/01/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/01/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/01/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
15/01/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
29/11/2023
GNSL
LETTER OF SUSPENSION E-MAILED
29/11/2023
CNSL
SUSPENSION LETTER WRITTEN
29/11/2023
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
29/11/2023
OTHE
CASE RETURNED TO EXAMINATION
08/11/2023
IUCN
NOTICE OF ALLOWANCE CANCELLED
08/11/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/08/2023
PUBO
PUBLISHED FOR OPPOSITION
08/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/07/2023
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
30/06/2023
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
23/06/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/05/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
18/05/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
18/05/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
18/05/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/05/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/04/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/04/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
26/04/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/04/2023
GNRT
NON-FINAL ACTION E-MAILED
10/04/2023
CNRT
NON-FINAL ACTION WRITTEN
10/04/2023
DOCK
ASSIGNED TO EXAMINER
31/03/2023
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
06/01/2023
ALIE
ASSIGNED TO LIE
05/01/2023
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
08/11/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/11/2022
NWAP
NEW APPLICATION ENTERED
25/10/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EPIC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.